When was ParaGen Technologies founded?

ParaGen Technologies was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is ParaGen Technologies located?

ParaGen Technologies is headquartered in Columbus, United States.

Who is the current CEO of ParaGen Technologies?

Ross Kayuha of ParaGen Technologies.

How many employees does ParaGen Technologies have?

As of Sep 30, 2026, the latest employee count at ParaGen Technologies is 3.

Is ParaGen Technologies a funded company?

ParaGen Technologies is a funded company, having raised a total of $11.6M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 08, 2017.

When was the latest funding round of ParaGen Technologies?

ParaGen Technologies' latest funding was a $***** Series A round on Nov 16, 2021, with participation from 0 investor.

Where does ParaGen Technologies rank among its competitors?

ParaGen Technologies ranks 85th amongst 353 active competitors, of which 138 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of ParaGen Technologies?

ParaGen Technologies' top competitors include Syngenta, Ginkgo Bioworks and Spark Therapeutics. Among them, Antheia secured the most recent funding round in January, 2026.

ParaGen Technologies - 2026 Company Profile, Team, Funding & Competitors

ParaGen Technologies is a series A company based in Columbus (United States), founded in 2016 by Flavio Lobato. It operates as a Developer of tissue engineering technologies. ParaGen Technologies has raised $11.6M in funding from Ikove Capital Partners. The company has 353 active competitors, including 138 funded and 79 that have exited. Its top competitors include companies like Syngenta, Ginkgo Bioworks and Spark Therapeutics.

Company Details

ParaGen Technologies is involved in developing tissue engineering technologies. They have developed their own synthetic nanofiber scaffolds, which replicates the extracellular matrix and enables healing by mimicking the physical structures present naturally in our body. Their technology can be used for wound care, orthopedics, vascular, and hernia repair.

Website: www.paragentechnologies.com/
Social
Email ID: *****@paragentechnologies.com
Phone Number: +1 **********

Key Metrics

Founded Year

2016

Location

Columbus, United States

Stage

Series A

Total Funding

$11.6M in 4 rounds

Latest Funding Round

Series A, Nov 16, 2021, $*****

Investors

Ikove Capital Partners & 3 more

Ranked

85^th among 353 active competitors

Employee Count

3 as on Sep 30, 2026

Similar Companies

Syngenta & 204 more

View ParaGen Technologies' full profile

ParaGen Technologies is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ParaGen Technologies CIN: 82-1779154 , United States, Active	Dec 31, 2015	-	-	-

ParaGen Technologies has raised a total funding of $11.6M over 4 rounds. Its first funding round was on Dec 08, 2017. ParaGen Technologies has 4 institutional investors.

Here is the list of recent funding rounds of ParaGen Technologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 16, 2021	4958983	Series A	9960180	4949534	6828163	8460919
Apr 23, 2019	9679748	Seed	6871188	5928985	6376246	4361438
Nov 29, 2018	1756555	Conventional Debt	9716469	9871920	6491063	7212716

Access funding benchmarks and valuations. Sign up today!

View details of ParaGen Technologies's funding rounds and investors

The founders of ParaGen Technologies is Flavio Lobato. Ross Kayuha is the CEO of ParaGen Technologies.

Here are the details of ParaGen Technologies' key team members:

Flavio Lobato: Co-Founder of ParaGen Technologies. They serve on the board of 1 company.
Ross Kayuha: CEO of ParaGen Technologies.
Contact Info: 1 email address

View details of ParaGen Technologies's Founder profiles and Board Members

ParaGen Technologies' employee count trend

ParaGen Technologies has 3 employees as of Sep 26. Here is ParaGen Technologies's employee count trend over the years:

Employee count trend for ParaGen Technologies

Uncover ParaGen Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ParaGen Technologies include Syngenta, Ginkgo Bioworks and Spark Therapeutics. Here is the list of Top 10 competitors of ParaGen Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Syngenta 2000, Basel (Switzerland), Acquired	Developer of technologies and sustainable farming practices for farmers	-	Analah Ventures, Europa	75/100
2nd	Ginkgo Bioworks 2008, Boston (United States), Public	Autonomous labs for biotechnology, empowering scientists to design the living world	$796M	Viking Global Investors, T. Rowe Price & 53 others	74/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
4th	Twist Bioscience 2013, San Francisco (United States), Public	Developer of a semiconductor-based DNA synthesis platform	$321M	Foresite Capital, Fidelity Investments & 39 others	72/100
5th	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	71/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Codexis 2002, Redwood City (United States), Public	Developer of high-performance enzymes for drug discovery	$111M	Vivo Capital, Malaysian Life Sciences Capital Fund ... & 12 others	68/100
8th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
9th	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
10th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
85th	ParaGen Technologies 2016, Columbus (United States), Series A	Developer of tissue engineering technologies	$11.6M	JointJourney, Circusitlogic & 2 others	42/100